Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 182c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of $1.90, $1.82 better than the analyst estimate of $0.08. Revenue for the quarter came in at $158.57 million versus the consensus estimate of $27.66 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Alpha's Drilling Confirms Second Target of Scale at Anagulu Copper-Gold Porphyry Project
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform